Structural modification of azolylacryloyl derivatives yields a novel class of covalent modifiers of hemoglobin as potential antisickling agents-Reference-Cited by-同舟云学术

Structural modification of azolylacryloyl derivatives yields a novel class of covalent modifiers of hemoglobin as potential antisickling agents

Published:2019 Issue:11 Volume:10 Page:1900-1906
ISSN:2040-2503
Container-title:MedChemComm
language:en
Short-container-title:Med. Chem. Commun.

Author:

Omar A. M.¹²³⁴⁵,David T.⁶⁷⁸⁹¹⁰,Pagare P. P.⁶⁷⁸⁹¹⁰,Ghatge M. S.⁶⁷⁸⁹¹⁰,Chen Q.¹¹¹²¹³,Mehta A.⁶⁷⁸⁹¹⁰,Zhang Y.⁶⁷⁸⁹¹⁰,Abdulmalik O.¹¹¹²¹³,Naghi A. H.¹²³⁴⁵,El-Araby M. E.¹²³⁴⁵,Safo M. K.⁶⁷⁸⁹¹⁰^ORCID

Affiliation:

1. Department of Pharmaceutical Chemistry

2. Faculty of Pharmacy

3. King Abdulaziz University

4. Jeddah 21589

5. Saudi Arabia

6. Department of Medicinal Chemistry

7. School of Pharmacy and Institute for Structural Biology

8. Drug Discovery and Development

9. Virginia Commonwealth University

10. Richmond

11. Division of Hematology

12. The Children's Hospital of Philadelphia

13. USA

Abstract

The intracellular polymerization and the concomitant sickling processes, central to the pathology of sickle cell disease, can be mitigated by increasing the oxygen affinity of sickle hemoglobin (HbS).

Funder

King Abdulaziz University

National Institute on Minority Health and Health Disparities

Publisher

Royal Society of Chemistry (RSC)

Subject

Pharmaceutical Science,Biochemistry,Drug Discovery,Molecular Medicine,Pharmacology,Organic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/MD/C9MD00291J

Reference17 articles.

1. Therapeutic Strategies to Alter the Oxygen Affinity of Sickle Hemoglobin

2. Hemoglobin–ligand binding: Understanding Hb function and allostery on atomic level

3. M. K. Safo and S.Bruno , in Allosteric Effectors of Hemoglobin: Past, Present and Future, Chemistry and Biochemistry of Oxygen Therapeutics , ed. A. Mozzarelli and S. Bettati , John Wiley & Sons, Ltd , 2011 , pp. 285–300 , Available from: http://onlinelibrary.wiley.com/doi/10.1002/9781119975427.ch21/summary

4. Study to Evaluate the Effect of GBT440 Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) - Full Text View - ClinicalTrials.gov [Internet], [Cited 2018 Mar 21], Available from: https://clinicaltrials.gov/ct2/show/NCT03036813

5. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease;Antioxidants & Redox Signaling;2024-01-23

2. Targeted modification of furan‐2‐carboxaldehydes into Michael acceptor analogs yielded long‐acting hemoglobin modulators with dual antisickling activities;Chemical Biology & Drug Design;2023-10-05

3. Isolation and Characterisation of Quercitrin as a Potent Anti-Sickle Cell Anaemia Agent from Alchornea cordifolia;Journal of Clinical Medicine;2022-04-13

4. Isolation and characterisation of quercitrin as a potent anti-sickle cell anaemia agent from Alchornea cordifolia;2021-11-23

5. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property;Expert Opinion on Therapeutic Patents;2021-11-01